#1 Clinical Trials Search in Europe

Resmetirom

Resmetirom, also known as MGL-3196, is an investigational drug being studied in clinical trials for its potential to treat Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) cirrhosis. These trials aim to evaluate the safety, tolerability, and effectiveness of Resmetirom in various patient populations, including those with severe renal impairment. The studies focus on assessing the drug’s impact on liver-related outcomes, biomarkers, and overall patient health.

Table of Contents

What is Resmetirom?

Resmetirom, also known by its alternative names MGL-3196 and Rezdiffra, is an investigational drug that is currently being studied for its potential in treating liver-related conditions[1][4]. It is a medication taken orally in tablet form, which means it can be easily administered at home without the need for injections or hospital visits[2].

What Conditions Does Resmetirom Treat?

Resmetirom is primarily being investigated for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)[1][2]. NAFLD is a condition where excess fat accumulates in the liver of people who drink little to no alcohol. In some cases, NAFLD can progress to a more severe form called Non-Alcoholic Steatohepatitis (NASH), which can lead to liver cirrhosis[3].

Specifically, Resmetirom is being studied for its potential to help patients with:

  • NAFLD: The early stages of fatty liver disease[1]
  • NASH: A more severe form of fatty liver disease with inflammation[3]
  • NASH Cirrhosis: Advanced liver scarring resulting from NASH[3]

How Does Resmetirom Work?

While the exact mechanism of action is not fully explained in the provided clinical trial data, Resmetirom is known to target certain aspects of liver function and fat metabolism. It appears to have effects on:

  • Hepatic fat fraction: This refers to the amount of fat in the liver, which Resmetirom may help reduce[1][2]
  • Lipid levels: The drug may help lower LDL-C (often called “bad” cholesterol) and triglycerides in the blood[2]
  • Liver stiffness: Resmetirom might help improve liver elasticity, which is a measure of liver health[2]

Clinical Trials and Research

Resmetirom is currently undergoing extensive clinical trials to evaluate its safety and effectiveness. Some key studies include:

  • MAESTRO-NAFLD-1: A 52-week study evaluating the safety and effects of Resmetirom on various biomarkers in patients with NAFLD[2]
  • MAESTRO-NAFLD-OLE: An open-label extension study to further assess the long-term safety and effects of Resmetirom[1]
  • MAESTRO-NASH-OUTCOMES: A study focusing on the effects of Resmetirom on clinical outcomes in patients with well-compensated NASH cirrhosis[3]

These trials are designed to measure various outcomes, including changes in liver fat, cholesterol levels, and the occurrence of liver-related events[3].

How is Resmetirom Administered?

Resmetirom is taken orally as a tablet, typically once daily in the morning[1][2]. The dosage being studied varies across trials, with common doses including:

  • 40 mg for some patients with NASH cirrhosis[1]
  • 80 mg daily[1][2]
  • 100 mg daily[1][2]

The appropriate dosage may depend on the specific condition being treated and individual patient factors.

Potential Side Effects and Safety

A primary focus of the ongoing clinical trials is to evaluate the safety and tolerability of Resmetirom. While specific side effects are not detailed in the provided information, the studies are closely monitoring:

  • The incidence of adverse events[1][2]
  • Changes in various biomarkers that could indicate safety concerns[2]
  • Long-term safety over extended periods of use[1]

It’s important to note that as an investigational drug, the full safety profile of Resmetirom is still being established through these clinical trials.

Future Research and Potential

Ongoing research is exploring the potential of Resmetirom beyond its primary focus on NAFLD and NASH. Some areas of investigation include:

  • Effects on liver-related outcomes: Studying how Resmetirom might impact the progression of liver disease and related complications[3]
  • Cardiovascular effects: Investigating potential benefits on heart health, given its effects on cholesterol levels[2]
  • Use in special populations: Studying how the drug behaves in patients with other conditions, such as severe renal impairment[4]

These ongoing studies will help determine the full potential of Resmetirom and identify the patients who might benefit most from this treatment.

Aspect Details
Drug Name Resmetirom (MGL-3196)
Conditions Studied Non-Alcoholic Fatty Liver Disease (NAFLD), NASH Cirrhosis
Administration Oral tablet, once daily
Dosages 40 mg, 80 mg, 100 mg (varies by study)
Study Durations 52 weeks to 3 years
Primary Outcomes Safety, tolerability, liver-related clinical outcomes
Secondary Outcomes Changes in liver fat, blood lipids, liver stiffness
Special Populations NASH cirrhosis patients, severe renal impairment
Measurement Tools MRI-PDFF, FibroScan, blood tests, MELD score

FAQ

  • What is Resmetirom and what conditions is it being studied for? Resmetirom, also known as MGL-3196, is an investigational drug being studied for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) cirrhosis. It is taken orally as a tablet.
  • How is Resmetirom administered in clinical trials? In the clinical trials, Resmetirom is typically administered as a once-daily oral tablet. The dosage varies across studies, with common doses being 40 mg, 80 mg, and 100 mg.
  • What are the main outcomes being measured in Resmetirom clinical trials? The main outcomes being measured include safety and tolerability (through monitoring adverse events), changes in liver fat content (measured by MRI-PDFF), changes in blood lipid levels (such as LDL-C and triglycerides), and in some studies, liver-related clinical outcomes in patients with NASH cirrhosis.
  • How long do the Resmetirom clinical trials typically last? The duration of Resmetirom clinical trials varies. Many of the phase 3 studies last for 52 weeks (1 year), while some extend up to 104 weeks (2 years) or even 3 years for long-term outcome studies.
  • Are there any special populations being studied in Resmetirom trials? Yes, some Resmetirom trials include special populations. For example, there are studies focusing on patients with compensated NASH cirrhosis and a study evaluating the drug in patients with severe renal impairment compared to healthy controls.

Ongoing Clinical Trials on Resmetirom

  • Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

    Not recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

    Not recruiting

    1 1
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +2

Glossary

  • Non-Alcoholic Fatty Liver Disease (NAFLD): A condition where excess fat builds up in the liver of people who drink little or no alcohol. It's the most common form of chronic liver disease in developed countries.
  • Non-Alcoholic Steatohepatitis (NASH): A more severe form of NAFLD, where in addition to fat accumulation, there is inflammation and liver cell damage, which can lead to fibrosis, cirrhosis, and liver failure.
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, including NASH.
  • MRI-PDFF: Magnetic Resonance Imaging – Proton Density Fat Fraction, a non-invasive method to measure the amount of fat in the liver.
  • LDL-C: Low-Density Lipoprotein Cholesterol, often referred to as 'bad' cholesterol, high levels of which are associated with increased risk of heart disease.
  • Triglycerides: A type of fat (lipid) found in your blood that your body uses for energy.
  • FibroScan: A non-invasive test that uses ultrasound-based technology to measure liver stiffness and fat content.
  • MELD score: Model for End-stage Liver Disease score, a numerical scale used to estimate the severity of chronic liver disease and predict survival.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Renal Impairment: A condition where the kidneys are not functioning properly, which can affect how drugs are processed and eliminated from the body.

References

  1. https://clinicaltrials.gov/study/NCT04951219
  2. https://clinicaltrials.gov/study/NCT04197479
  3. https://clinicaltrials.eu/trial/study-on-the-effects-of-resmetirom-in-patients-with-well-compensated-non-alcoholic-steatohepatitis-nash-cirrhosis/
  4. https://clinicaltrials.gov/study/NCT06397872